THE AMERICAN EDIT

Spinal muscular atrophy

The latest reporting, guides and features on Spinal muscular atrophy.

Exterior of an FDA laboratory building on the White Oak campus

FDA investigates tumor risk after Zolgensma gene therapy

The agency recommends monitoring patients who received Zolgensma or Itvisma while it reviews whether to take regulatory action.

November 8, 2026 · 2 min read